

Publications

1. Nardelli DT, Luedtke JO, Munson EL, Warner TF, Callister SM, Schell RF. Significant differences between the *Borrelia*-infection and *Borrelia*-vaccination and -infection models of Lyme arthritis in C3H/HeN mice. *FEMS Immunol Med Microbiol*. 2010 July 1.
2. LaFleur RL, Callister SM, Dant JC, Jobe DA, Lovrich SD, Warner TF, Wasmoen TL, Schell RF. One-year duration of immunity induced by vaccination with a canine Lyme disease bacterin. *Clin Vaccine Immunol*. 2010 May; 17(5): 870-874. PMID: PMC2863397.
3. Little SE, Heise SR, Blagburn BL, Callister SM, Mead PS. Lyme borreliosis in dogs and humans in the USA. *Trends Parasitol*. 2010 Apr; 26(4): 213-218.
4. LaFleur RL, Dant JC, Wasmoen TL, Callister SM, Jobe DA, Lovrich SD, Warner TF, Abdelmagid O, Schell RF. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. *Clin Vaccine Immunol*. 2009 Feb; 16(2): 253-259. PMID: PMC2643534.
5. Kotloski NJ, Nardelli DT, Peterson SH, Torrealba JR, Warner TF, Callister SM, Schell RF. Interleukin-23 is required for development of arthritis in mice vaccinated and challenged with *Borrelia* species. *Clin Vaccine Immunol*. 2008 Aug; 15(8): 1199-1207. PMID: PMC2519303.
6. Nardelli DT, Kevin Luk KH, Kotloski NJ, Warner TF, Torrealba JR, Callister SM, Schell RF. Role of IL-17, transforming growth factor- β , and IL-6 in the development of arthritis and production of anti-outer surface protein A borreliacidal antibodies in *Borrelia*-vaccinated and -challenged mice. *FEMS Immunol Med Microbiol*. 2008 Jul; 53(2): 265-274.
7. Jobe DA, Lovrich SD, Asp KE, Mathiason MA, Albrecht SE, Schell RF, Callister SM. Significantly improved accuracy of diagnosis of early Lyme disease by peptide enzyme-linked immunosorbent assay based on the borreliacidal antibody epitope of *Borrelia burgdorferi* OspC. *Clin Vaccine Immunol*. 2008 Jun; 15(6): 981-985. PMID: PMC2446615.
8. Peterson SH, Nardelli DT, Warner TF, Callister SM, Torrealba JR, Schell RF. Anti-p19 antibody treatment exacerbates Lyme arthritis and enhances borreliacidal activity. *Clin Vaccine Immunol*. 2007 May; 14(5): 510-517. PMID: PMC1865634.
9. Lovrich SD, LaFleur RL, Jobe DA, Johnson JC, Asp KE, Schell RF, Callister SM. Borreliacidal OspC antibody response of canines with Lyme disease differs significantly from that of humans with Lyme disease. *Clin Vaccine Immunol*. 2007 May; 14(5): 635-637. PMID: PMC1865635.
10. Jobe DA, Nelson JA, Adam MD, Martin SA, Jr. Lyme disease in urban areas, Chicago. *Emerg Infect Dis*. 2007; 13(11): 1799-1800.
11. Nardelli DT, Warner TF, Callister SM, Schell RF. Anti-CD25 antibody treatment of mice vaccinated and challenged with *Borrelia* spp. does not exacerbate arthritis but inhibits borreliacidal antibody production. *Clin Vaccine Immunol*. 2006 Aug; 13(8): 884-891. PMID: PMC1539113.
12. Jobe DA, Lovrich SD, Nelson JA, Velat TC, Anchor C, Koeune T, Martin SA, Jr. *Borrelia burgdorferi* in *Ixodes scapularis* ticks, Chicago area. *Emerg Infect Dis*. 2006 Jun; 12(6): 1039-1041.
13. Amlong CA, Nardelli DT, Peterson SH, Warner TF, Callister SM, Schell RF. Anti-interleukin-15 prevents arthritis in *Borrelia*-vaccinated and -infected mice. *Clin Vaccine Immunol*. 2006 Feb; 13(2): 289-296. PMID: PMC1391944.
14. Munson EL, Nardelli DT, Luk KH, Remington MC, Callister SM, Schell RF. Interleukin-6 promotes anti-OspA borreliacidal antibody production in vitro. *Clin Vaccine Immunol*. 2006 Jan; 13(1): 19-25. PMID: PMC1356618.
15. Lovrich SD, Jobe DA, Schell RF, Callister SM. Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human Lyme disease and do not occur in mice or hamsters. *Clin Diagn Lab Immunol*. 2005 Jun; 12(6): 746-751. PMID: PMC1151971.

16. Nardelli DT, Cloute JP, Luk KH, Torrealba J, Warner TF, Callister SM, Schell RF. CD4(+) CD25(+) T cells prevent arthritis associated with *Borrelia* vaccination and infection. *Clin Diagn Lab Immunol*. 2005 Jun; 12(6): 786-792. PMID: PMC1151965.
17. Nardelli DT, Burchill MA, England DM, Torrealba J, Callister SM, Schell RF. Association of CD4+ CD25+ T cells with prevention of severe destructive arthritis in *Borrelia burgdorferi*-vaccinated and challenged gamma interferon-deficient mice treated with anti-interleukin-17 antibody. *Clin Diagn Lab Immunol*. 2004 Nov; 11(6): 1075-1084. PMID: PMC524754.
18. Munson EL, DeCoster DJ, Nardelli DT, England DM, Callister SM, Schell RF. Neutralization of gamma interferon augments borreliacidal antibody production and severe destructive Lyme arthritis in C3H/HeJ mice. *Clin Diagn Lab Immunol*. 2004 Jan; 11(1): 35-41. PMID: PMC321347.
19. Jobe DA, Lovrich SD, Schell RF, Callister SM. C-terminal region of outer surface protein C binds borreliacidal antibodies in sera from patients with Lyme disease. *Clin Diagn Lab Immunol*. 2003 Jul; 10(4): 573-578.
20. Burchill MA, Nardelli DT, England DM, DeCoster DJ, Christopherson JA, Callister SM, Schell RF. Inhibition of interleukin-17 prevents the development of arthritis in vaccinated mice challenged with *Borrelia burgdorferi*. *Infect Immun*. 2003 Jun; 71(6): 3437-3442. PMID: PMC155727.
21. Christopherson JA, Munson EL, England DM, Croke CL, Remington MC, Molitor ML, DeCoster DJ, Callister SM, Schell RF. Destructive arthritis in vaccinated interferon gamma-deficient mice challenged with *Borrelia burgdorferi*: Modulation by tumor necrosis factor alpha. *Clin Diagn Lab Immunol*. 2003 Jan; 10(1): 44-52. PMID: PMC145283.
22. Munson EL, DuChateau BK, Jensen JR, Callister SM, DeCoster DJ, Schell RF. Gamma interferon inhibits production of anti-OspA borreliacidal antibody in vitro. *Clin Diagn Lab Immunol*. 2002 Sep; 9(5): 1095-1101. PMID: PMC120068.
23. Callister SM, Jobe DA, Agger WA, Schell RF, Kowalski TJ, Lovrich SD, Marks JA. Ability of the borreliacidal antibody test to confirm Lyme disease in clinical practice. *Clin Diagn Lab Immunol*. 2002 Jul; 9(4): 908-912. PMID: PMC120016.
24. Jackson CA, Lovrich SD, Agger WA, Callister SM. Reassessment of a midwestern Lyme disease focus for *Borrelia burgdorferi* and the human granulocytic ehrlichiosis agent. *J Clin Microbiol*. 2002 Jun; 40(6): 2070-2073. PMID: PMC130725.
25. Remington MC, Munson EL, Callister SM, Molitor ML, Christopherson JA, DeCoster DJ, Lovrich SD, Schell RF. Interleukin-6 enhances production of anti-OspC immunoglobulin G2b borreliacidal antibody. *Infect Immun*. 2001 Jul; 69(7): 4268-4275. PMID: PMC98496.
26. Callister SM, Jobe DA, Schell RF, Lovrich SD, Onheiber KL, Korshus JB. Detection of borreliacidal antibodies in dogs after challenge with *Borrelia burgdorferi*-infected *Ixodes scapularis* ticks. *J Clin Microbiol*. 2000 Oct; 38(10): 3670-3674. PMID: PMC87454.
27. Munson EL, DuChateau BK, Jobe DA, Lovrich SD, Callister SM, Schell RF. Production of borreliacidal antibody to outer surface protein A in vitro and modulation by interleukin-4. *Infect Immun*. 2000 Oct; 68(10): 5496-5501. PMID: PMC101497.
28. Vena RM, Munson EL, DeCoster DJ, Croke CL, Fett DB, Callister SM, Schell RF. Flow cytometric testing of susceptibilities of *Mycobacterium avium* to amikacin, ciprofloxacin, clarithromycin and rifabutin in 24 hours. *Clin Microbiol Infect*. 2000 Jul; 6(7): 368-375.
29. Croke CL, Munson EL, Lovrich SD, Christopherson JA, Remington MC, England DM, Callister SM, Schell RF. Occurrence of severe destructive Lyme arthritis in hamsters vaccinated with outer surface protein A and challenged with *Borrelia burgdorferi*. *Infect Immun*. 2000 Feb; 68(2): 658-663. PMID: PMC97189.
30. Wieneke CA, Lovrich SD, Callister SM, Jobe DA, Marks JA, Schell RF. Evaluation of whole-cell and OspC enzyme-linked immunosorbent assays for discrimination of early Lyme borreliosis from OspA vaccination. *J Clin Microbiol*. 2000 Jan; 38(1): 313-317. PMID: PMC88715.

31. Jobe DA, Rawal N, Schell RF, Callister SM. Detection of borreliacidal antibodies in Lyme borreliosis patient sera containing antimicrobial agents. *Clin Diagn Lab Immunol*. 1999 Nov; 6(6): 930-933. PMID: PMC95800.
32. Moore AV, Kirk SM, Callister SM, Mazurek GH, Schell RF. Safe determination of susceptibility of *Mycobacterium tuberculosis* to antimycobacterial agents by flow cytometry. *J Clin Microbiol*. 1999 Mar; 37(3): 479-483.
33. DuChateau BK, Munson EL, England DM, Lovrich SD, Callister SM, Jensen JR, Schell RF. Macrophages interact with enriched populations of distinct T lymphocyte subsets for the induction of severe destructive Lyme arthritis. *J Leukoc Biol*. 1999 Feb; 65(2): 162-170.
34. Rousselle JC, Callister SM, Schell RF, Lovrich SD, Jobe DA, Marks JA, Wieneke CA. Borreliacidal antibody production against outer surface protein C of *Borrelia burgdorferi*. *J Infect Dis*. 1998 Sep; 178(3): 733-741.
35. Schell RF, Callister SM, Kirk SM. Flow cytometric susceptibility testing of *Mycobacterium tuberculosis*. *Am Clin Lab*. 1998; 17: 24-25.
36. Kirk SM, Schell RF, Moore AV, Callister SM, Mazurek GH. Flow cytometric testing of susceptibilities of *Mycobacterium tuberculosis* isolates to ethambutol, isoniazid, and rifampin in 24 hours. *J Clin Microbiol*. 1998 Jun; 36(6): 1568-1573. PMID: PMC104878.
37. Jensen JR, DuChateau BK, Munson EL, Callister SM, Schell RF. Inhibition of the production of anti-OspA borreliacidal antibody with T cells from hamsters vaccinated against *Borrelia burgdorferi*. *Infect Immun*. 1998 Apr; 66(4): 1507-1512. PMID: PMC108081.
38. Callister SM, Schell RF, Lovrich SD. Enhanced sensitivity of the borreliacidal-antibody test. *Mayo Clin Proc*. 1997 Nov; 72(11): 1093-1094.
39. DuChateau BK, Jensen JR, England DM, Callister SM, Lovrich SD, Schell RF. Macrophages and enriched populations of T lymphocytes interact synergistically for the induction of severe, destructive Lyme arthritis. *Infect Immun*. 1997 Jul; 65(7): 2829-2836. PMID: PMC175398.
40. Bakken LL, Callister SM, Wand PJ, Schell RF. Interlaboratory comparison of test results for detection of Lyme disease by 516 participants in the Wisconsin State Laboratory of Hygiene/College of American Pathologists Proficiency Testing program. *J Clin Microbiol*. 1997 Mar; 35(3): 537-543. PMID: PMC229622.
41. Kirk SM, Callister SM, Lim LC, Schell RF. Rapid susceptibility testing of *Candida albicans* by flow cytometry. *J Clin Microbiol*. 1997 Feb; 35(2): 358-363. PMID: PMC229580.
42. Padilla ML, Callister SM, Schell RF, Bryant GL, Jobe DA, Lovrich SD, DuChateau BK, Jensen JR. Characterization of the protective borreliacidal antibody response in humans and hamsters after vaccination with a *Borrelia burgdorferi* outer surface protein A vaccine. *J Infect Dis*. 1996 Oct; 174(4): 739-746.
43. Callister SM, Jobe DA, Schell RF, Pavia CS, Lovrich SD. Sensitivity and specificity of the borreliacidal-antibody test during early Lyme disease: A "gold standard"? *Clin Diagn Lab Immunol*. 1996 Jul; 3(4): 399-402. PMID: PMC170357.
44. DuChateau BK, England DM, Callister SM, Lim LC, Lovrich SD, Schell RF. Macrophages exposed to *Borrelia burgdorferi* induce Lyme arthritis in hamsters. *Infect Immun*. 1996 Jul; 64(7): 2540-2547. PMID: PMC174108.
45. Nicholls TH, Callister SM. Lyme disease spirochetes in ticks collected from birds in midwestern United States. *J Med Entomol*. 1996 May; 33(3): 379-384.
46. Creson JR, Lim LC, Glowacki NJ, Callister SM, Schell RF. Detection of anti-*Borrelia burgdorferi* antibody responses with the borreliacidal antibody test, indirect fluorescent-antibody assay performed by flow

cytometry, and western immunoblotting. *Clin Diagn Lab Immunol*. 1996 Mar; 3(2): 184-190. PMID: PMC170272.

47. Lovrich SD, Callister SM, DuChateau BK, Lim LC, Winfrey J, Day SP, Schell RF. Abilities of OspA proteins from different seroprotective groups of *Borrelia burgdorferi* to protect hamsters from infection. *Infect Immun*. 1995 Jun; 63(6): 2113-2119.
48. Callister SM, Schell RF. Importance of protective borreliacidal antibodies in Lyme disease immunity and serodiagnosis. *J Infect Dis*. 1994 Aug; 170(2): 499-500.
49. Lovrich SD, Callister SM, Lim LC, DuChateau BK, Schell RF. Seroprotective groups of Lyme borreliosis spirochetes from North America and Europe. *J Infect Dis*. 1994 Jul; 170(1): 115-121.
50. Callister SM, Schell RF, Lim LC, Jobe DA, Case KL, Bryant GL, Molling PE. Detection of borreliacidal antibodies by flow cytometry. An accurate, highly specific serodiagnostic test for Lyme disease. *Arch Intern Med*. 1994 Jul 25; 154(14): 1625-1632.
51. Lim LC, England DM, DuChateau BK, Glowacki NJ, Creson JR, Lovrich SD, Callister SM, Jobe DA, Schell RF. Development of destructive arthritis in vaccinated hamsters challenged with *Borrelia burgdorferi*. *Infect Immun*. 1994 Jul; 62(7): 2825-2833.
52. Liu YF, Lim LC, Schell K, Lovrich SD, Callister SM, Schell RF. Differentiation of borreliacidal activity caused by immune serum or antimicrobial agents by flow cytometry. *Clin Diagn Lab Immunol*. 1994 Mar; 1(2): 145-149. PMID: PMC368217.
53. Jobe DA, Callister SM, Lim LC, Lovrich SD, Schell RF. Ability of canine Lyme disease vaccine to protect hamsters against infection with several isolates of *Borrelia burgdorferi*. *J Clin Microbiol*. 1994 Mar; 32(3): 618-622. PMID: PMC263096.
54. Lim LC, Liu YF, Schell K, Lovrich SD, Callister SM, Schell RF. Detection of borreliacidal antibody by using acridine orange and flow cytometry. *Clin Diagn Lab Immunol*. 1994 Jan; 1(1): 44-50. PMID: PMC368194.
55. Lovrich SD, Callister SM, Lim LC, Schell RF. Seroprotective groups among isolates of *Borrelia burgdorferi*. *Infect Immun*. 1993 Oct; 61(10): 4367-4374. PMID: PMC281168.
56. Jobe DA, Callister SM, Schell RF. Recovery of *Borrelia burgdorferi* by filtration. *J Clin Microbiol*. 1993 Jul; 31(7): 1896-1898. PMID: PMC265653.
57. Callister SM, Schell RF, Case KL, Lovrich SD, Day SP. Characterization of the borreliacidal antibody response to *Borrelia burgdorferi* in humans: A serodiagnostic test. *J Infect Dis*. 1993 Jan; 167(1): 158-164.
58. Bakken LL, Case KL, Callister SM, Bourdeau NJ, Schell RF. Performance of 45 laboratories participating in a proficiency testing program for Lyme disease serology. *JAMA*. 1992 Aug 19; 268(7): 891-895.
59. Agger WA, Callister SM, Jobe DA. In vitro susceptibilities of *Borrelia burgdorferi* to five oral cephalosporins and ceftriaxone. *Antimicrob Agents Chemother*. 1992 Aug; 36(8): 1788-1790. PMID: PMC192050.
60. Schmitz JL, Schell RF, Callister SM, Lovrich SD, Day SP, Coe JE. Immunoglobulin G2 confers protection against *Borrelia burgdorferi* infection in LSH hamsters. *Infect Immun*. 1992 Jul; 60(7): 2677-2682. PMID: PMC257220.
61. Sachsenmeier KF, Schell K, Morrissey LW, Pennell DR, West RM, Callister SM, Schell RF. Detection of borreliacidal antibodies in hamsters by using flow cytometry. *J Clin Microbiol*. 1992 Jun; 30(6): 1457-1461. PMID: PMC265310.
62. Schmitz JL, Lovrich SD, Callister SM, Schell RF. Depletion of complement and effects on passive transfer of resistance to infection with *Borrelia burgdorferi*. *Infect Immun*. 1991 Oct; 59(10): 3815-3818. PMID: PMC258956.
63. Callister SM, Schell RF, Lovrich SD. Lyme disease assay which detects killed *Borrelia burgdorferi*. *J Clin Microbiol*. 1991 Sep; 29(9): 1773-1776. PMID: PMC270208.
64. Nelson JA, Bouseman JK, Kitron U, Callister SM, Harrison B, Bankowski MJ, Peeples ME, Newton BJ, Anderson JF. Isolation and characterization of *Borrelia burgdorferi* from Illinois *Ixodes dammini*. *J Clin Microbiol*. 1991 Aug; 29(8): 1732-1734. PMID: PMC270194.

65. Lovrich SD, Callister SM, Schmitz JL, Alder JD, Schell RF. Borreliacidal activity of sera from hamsters infected with the Lyme disease spirochete. *Infect Immun*. 1991 Aug; 59(8): 2522-2528. PMID: PMC258050.
66. Schmitz JL, Schell RF, Lovrich SD, Callister SM, Coe JE. Characterization of the protective antibody response to *Borrelia burgdorferi* in experimentally infected LSH hamsters. *Infect Immun*. 1991 Jun; 59(6): 1916-1921. PMID: PMC257943.
67. Agger WA, Case KL, Bryant GL, Callister SM. Lyme disease: Clinical features, classification, and epidemiology in the upper Midwest. *Medicine (Baltimore)*. 1991 Mar; 70(2): 83-90.
68. Callister SM, Nelson JA, Schell RF, Jobe DA, Bautz R, Agger WA, Coggins J. Survey for *Ixodes* spp. and *Borrelia burgdorferi* in southeastern Wisconsin and northeastern Illinois. *J Clin Microbiol*. 1991 Feb; 29(2): 403-406. PMID: PMC269778.
69. Callister SM, Case KL, Agger WA, Schell RF, Johnson RC, Ellingson JL. Effects of bovine serum albumin on the ability of Barbour-Stoenner-Kelly medium to detect *Borrelia burgdorferi*. *J Clin Microbiol*. 1990 Feb; 28(2): 363-365. PMID: PMC269609.
70. Hejka A, Schmitz JL, England DM, Callister SM, Schell RF. Histopathology of Lyme arthritis in LSH hamsters. *Am J Pathol*. 1989 May; 134(5): 1113-1123. PMID: PMC1879892.
71. Callister SM, Agger WA, Schell RF, Brand KM. Efficacy of the urinary bladder for isolation of *Borrelia burgdorferi* from naturally infected, wild *Peromyscus leucopus*. *J Clin Microbiol*. 1989 Apr; 27(4): 773-774. PMID: PMC267416.
72. Callister SM, Agger WA, Schell RF, Ellingson JL. *Borrelia burgdorferi* infection surrounding La Crosse, Wis. *J Clin Microbiol*. 1988 Dec; 26(12): 2632-2636. PMID: PMC266960.

Studies with Other Microorganisms

1. Schwan WR, Briska A, Stahl B, Wagner TK, Zentz E, Henkhaus J, Lovrich SD, Agger WA, Callister SM, DuChateau B, Dykes CW. Use of optical mapping to sort uropathogenic *Escherichia coli* strains into distinct subgroups. *Microbiology*. 2010 Jul; 156(Pt 7): 2124-2135.
2. Fredricks BA, DeCoster DJ, Kim Y, Sparks N, Callister SM, Schell RF. Rapid pyrazinamide susceptibility testing of *Mycobacterium tuberculosis* by flow cytometry. *J Microbiol Methods*. 2006 Nov; 67(2): 266-272.
3. Bly BL, Knutson MG, Sandheinrich MB, Gray BR, Jobe DA. Flow cytometry used to assess genetic damage in frogs from farm ponds. *Journal of the Iowa Academy of Science*. 2006; 111(3-4): 67-70.
4. DeCoster DJ, Vena RM, Callister SM, Schell RF. Susceptibility testing of *Mycobacterium tuberculosis*: Comparison of the BACTEC TB-460 method and flow cytometric assay with the proportion method. *Clin Microbiol Infect*. 2005 May; 11(5): 372-378.
5. Schlicht MJ, Lovrich SD, Sartin JS, Karpinsky P, Callister SM, Agger WA. High prevalence of genital mycoplasmas among sexually active young adults with urethritis or cervicitis symptoms in La Crosse, Wisconsin. *J Clin Microbiol*. 2004; 42: 4636-4640. PMID: PMC522307.
6. Norden MA, Kurzynski TA, Bownds SE, Callister SM, Schell RF. Rapid susceptibility testing of *Mycobacterium tuberculosis* (H37Ra) by flow cytometry. *J Clin Microbiol*. 1995 May; 33(5): 1231-1237.
7. Callister SM, Agger WA. Enumeration and characterization of *Aeromonas hydrophila* and *Aeromonas caviae* isolated from grocery store produce. *Appl Environ Microbiol*. 1987 Feb; 53(2): 249-253.
8. Agger WA, Callister SM. Intestinal infections with *Aeromonas caviae*. *Ann Intern Med*. 1987 Mar; 106(3): 479.
9. Agger WA, Cogbill TH, Busch HM, Jr, Landercasper J, Callister SM. Wounds caused by corn-harvesting machines: An unusual source of infection due to Gram-negative bacilli. *Rev Infect Dis*. 1986 Nov-Dec; 8(6): 927-931.

Cancer Studies

1. Pingali SR, Mathiason MA, Lovrich SD, Go RS. Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation. *Clin Lymphoma Myeloma*. 2009; 9: E25-29.
2. Go RS, Jobe DA, Asp KE, Callister SM, Mathiason MA, Meyer LA, Bottner WA, Cole CE, Farnen JP, Frisby KA. Circulating endothelial cells in patients with chronic lymphocytic leukemia. *Ann Hematol*. 2008 May; 87(5): 369-373.
3. Go RS, Lovrich SD, Callister SM, Meyer LA, Bottner WA, Farnen JP. Human cyclic thrombocytopenia and *Anaplasma* spp. infection. *Eur J Haematol*. 2005 Feb; 74(2): 182-183.

Reviews and Book Chapters

1. Nardelli DT, Munson EL, Callister SM, Schell RF. Human Lyme disease vaccines: Past and future concerns. *Future Microbiol*. 2009; 4:457-469.
2. Callister SM. Serodiagnosis or prevention of canine Lyme disease. *Canadian Vet*. 2008 Mar/Apr; 1.
3. Nardelli DT, Callister SM, Schell RF. Lyme arthritis: Current concepts and a change in paradigm. *Clin Vaccine Immunol*. 2008 Jan; 15(1): 21-34. PMID: PMC2223850.
4. Schell RF, Nardelli DT, DeCoster DJ, Kirk SM, Callister SM. *Mycobacterium tuberculosis* susceptibility testing by flow cytometry. In: Current protocols in cytometry, Unit 11.7. New York: Wiley; 2004.
5. Callister SM, Jobe DA, Schell RF. Detection of borreliacidal antibodies by flow cytometry. In: Current protocols in cytometry, Unit 11.5. New York: Wiley; 2003.
6. Jobe DA, Callister SM, Lovrich SD, Schell RF. Rapid susceptibility testing of Lyme disease spirochetes by flow cytometry. *J Spiro Tick-Borne Dis*. 2000; 6: 105-111.
7. Bernhardt M, Almer LS, Munson EL, Callister SM, Schell RF. Detection of bacteria in blood: Centrifugation and filtration. In: Lederberg J, Bloom BR, Alexander M, editors. Encyclopedia of microbiology. 2nd ed. San Diego: Academic Press; 2000. p. 9-14.
8. Callister SM, Jobe DA, Schell RF. The impact of vaccination against Lyme borreliosis on laboratory serodiagnosis. *Clin Microbiol Newsl*. 1999 August 15; 21(16): 129-132.
9. Schell RF, Callister SM. Hamster model of Lyme arthritis. In: Zak O, Sande MA, editors. Handbook of animal models of infection. London: Academic Press; 1999. p. 347-352.
10. Callister SM, Jobe DA, Schell RF. Detection of borreliacidal antibodies by flow cytometry. In: Current protocols in cytometry Suppl. 7, Unit 11.5. New York: Wiley; 1999.
11. Schell RF, Moore AV, Vena RM, Kirk SM, Callister SM. Flow cytometric testing of susceptibilities of *Mycobacterium tuberculosis*. *Clin Immunol Newsl*. 1999; 19(1-2): 14-16.
12. Kirk SM, Mazurek GH, Callister SM, Moore AV, Schell RF. *Mycobacterium tuberculosis* susceptibility results in 24 hours by using flow cytometry. *Clin Microbiol Newsl*. 1998 May 15; 20(10): 83-87.
13. Callister SM, Schell RF. Laboratory serodiagnosis of Lyme borreliosis *J Spiro Tick-Borne Dis*. 1998; 5: 4-9.
14. Schell RF, Callister SM, Jobe DA, DuChateau BK. The borreliacidal antibody test: An alternative approach for confirming Lyme borreliosis. *J Spiro Tick-Borne Dis*. 1997; 4: 4-6.
15. Munson EL, DuChateau BK, Jobe DA, Padilla ML, Lovrich SD, Jensen JR, Lim LC, Schmitz JL, Callister SM, Schell RF. Hamster model of Lyme borreliosis. *J Spiro Tick-Borne Dis*. 1996; 3: 15-21.
16. Callister SM, Schell RF. Flow cytometric detection of borreliacidal antibodies: A test for immune status and specific serodiagnosis of Lyme disease. *Clin Immunol Newsl*. 1995; 15(4): 41-46.
17. Callister SM, Schell RF, Lovrich SD, Jobe DA. Lyme disease: Laboratory diagnosis and serologic testing. *Endeavour*. 1994; 18(2): 80-84.

18. Bakken LL, Callister SM, Case KL, Schell RF. Wisconsin Proficiency Program for Lyme disease: A program for improving detection of antibodies to *Borrelia burgdorferi*. *Clin Immunol Newsl.* 1991 Dec; 11(12): 187-189.